Read Important Information on Helixate® FS, Antihemophilic Factor (Recombinant)

Read Important Information on Helixate® FS, Antihemophilic Factor (Recombinant)

For adult and pediatric patients with hemophilia A

Help Him REACH HIGHER With Long-lasting Protection

AFSTYLA, with twice-weekly dosing available, delivers long-lasting bleed protection using a novel single-chain design

Explore the benefits of AFSTYLA

Twice-weekly dosing

FDA approved for 2x–3x weekly dosing

time-to-trough data

ZERO bleeds (median AsBR*)

In all studied populations

Explore AFSTYLA efficacy

*Annualized spontaneous bleeding rate in clinical trials (IQR=0–2.4 for patients ≥12 years; 0–2.2 for patients <12 years).


Enhanced von Willebrand
factor affinity extends time
in circulation1

Learn about the
science of AFSTYLA

Getting your patients started is simple

  • Start patient on AFSTYLA with a free 30-day trial
  • Fill out an AFSTYLA Patient Referral form to start the trial,
    enroll your patient in the AFSTYLA Support program, and
    begin a benefits investigation
  • Fax the completed form to My SourceSM at 1-844-727-2757

See what additional resources are available for you and your patients


to get detailed information
about services available to
your patients

Monday–Friday, 8 am to 8 pm ET

Find out first!

Sign up and stay up to date. Get breaking news and information about AFSTYLA.

Email address

Reference: 1. Zollner S, Raquet E, Claar P, et al. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2014;134(1):125-131.

You are now leaving the current website.

Do you want to continue?

No Yes